Plus Therapeutics establishes $17.35M at-the-market equity offering facility

Filed June 5, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• high

  Company can now sell up to $17.35 million of common stock directly on Nasdaq through Canaccord Genuity as sales agent, with no obligation to sell any shares. Sales will occur at the company's discretion based on market conditions.

  Item 1.01 verify on EDGAR →
• medium

  Proceeds will be used for general corporate purposes and working capital, providing flexibility but no specific allocation to drug development programs or clinical trials.

  Item 1.01 verify on EDGAR →
• medium

  Company will pay 3% commission on gross proceeds plus $75,000 in expenses to Canaccord Genuity. Sales cannot begin until SEC declares the June 2 Form S-3 registration statement effective.

  Item 1.01 verify on EDGAR →